Budesonide yields durable reduction in eGFR for IgA nephropathy
For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in estimated glomerular filtration rate (eGFR) than placebo, ...
Aug 22, 2023
0
1